![Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology](https://jasn.asnjournals.org/content/jnephrol/23/10/1663/F6.large.jpg?width=800&height=600&carousel=1)
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Imp
![Frontiers | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages Frontiers | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages](https://www.frontiersin.org/files/Articles/420947/fphar-09-01536-HTML/image_m/fphar-09-01536-g002.jpg)
Frontiers | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
![Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology](https://molpharm.aspetjournals.org/sites/default/files/highwire/molpharm/91/5.cover-source.jpg)
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology
![APExBIO - Bardoxolone methyl|IKK inhibitor, potent antioxidant inflammation modulator|CAS# 218600-53-4 APExBIO - Bardoxolone methyl|IKK inhibitor, potent antioxidant inflammation modulator|CAS# 218600-53-4](http://www.apexbt.com/pub/media/prod_images/a/3/a3221.png)
APExBIO - Bardoxolone methyl|IKK inhibitor, potent antioxidant inflammation modulator|CAS# 218600-53-4
Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites | Journal of Medicinal Chemistry
![Molecules | Free Full-Text | Transcription Factors as Therapeutic Targets in Chronic Kidney Disease | HTML Molecules | Free Full-Text | Transcription Factors as Therapeutic Targets in Chronic Kidney Disease | HTML](https://www.mdpi.com/molecules/molecules-23-01123/article_deploy/html/images/molecules-23-01123-g001-550.jpg)
Molecules | Free Full-Text | Transcription Factors as Therapeutic Targets in Chronic Kidney Disease | HTML
![Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/371/3/642/F2.large.jpg)
Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics
![Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - Kidney International Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - Kidney International](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/93bd8720-4391-4d38-a165-6ba37c6fbd4e/gr1_lrg.jpg)
Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - Kidney International
![Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl - Journal of Cardiac Failure Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl - Journal of Cardiac Failure](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/82802f72-5a31-4616-b8d0-2ee9e94e0b69/gr1.jpg)
Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl - Journal of Cardiac Failure
![Antioxidants | Free Full-Text | Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling | HTML Antioxidants | Free Full-Text | Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling | HTML](https://www.mdpi.com/antioxidants/antioxidants-10-00258/article_deploy/html/images/antioxidants-10-00258-g001.png)
Antioxidants | Free Full-Text | Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling | HTML
![Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease - ScienceDirect Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253819305034-fx1.jpg)